Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Japan Firms Joining Fray in siRNA Drug Development; Takeda Could File as Early as FY2025
June 6, 2023
- Japan Approves 1st Gene Panel Testing for IRD
June 6, 2023
- Xocova Given to Over 50,000 Patients in 6 Months: Shionogi
June 6, 2023
- Pfizer Japan Seeks Lupus Nephritis Nod for Rituxan Biosimilar
June 6, 2023
- Kaken, Dong-Wha Ink License Pact for Ecclock in South Korea
June 6, 2023
- Gilead Files HIV Med Lenacapavir in Japan
June 5, 2023
- Women Exec Ratio 14.7% among TSE Prime Drug Makers, Wholesalers; Astellas Leads the Way at 30%
June 2, 2023
- CSL Behring Launches App to Manage HAE Records
June 2, 2023
- Japan Pharma Market Grows for 2 Years Running with 2.6% Rise in FY2022: IQVIA
June 2, 2023
- Shionogi Shoots for Doubling Revenue to 800 Billion Yen by FY2030
June 2, 2023
- Ferring Japan Recalling Fertility Drug Lutinus after Bacteria Detection
June 2, 2023
- Shionogi to End Crestor Sales, AstraZeneca to Go Solo
June 2, 2023
- Pharma Companies in Japan Raising Retirement Age, Extending Rehiring: Jiho Poll
June 1, 2023
- Nipro Pharma Submits Business Improvement Plan after GMP Issues
June 1, 2023
- AnGes Seeks Full Approval for Gene Therapy Collategene in Japan
June 1, 2023
- Braftovi/Mektovi Filed for Thyroid Cancer in Japan: Ono
June 1, 2023
- Maruho’s Bepio Lotion Hits Japan Pharmacy Shelves
June 1, 2023
- AbbVie Aims to Double Japan Sales to 200 Billion Yen by 2030: Local Chief
May 31, 2023
- Jeremy Grossas to Head Up Merck Biopharma Japan
May 30, 2023
- Nobelpharma Gets EU Nod for Hyftor
May 30, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…